Accumulate Ipca Laboratories; target of Rs 950: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Ipca Laboratories with a target price of Rs 950 in its research report dated November 15, 2022.07-12-2022
07-12-2022
IPCA LABORATORIES LTD. - 524494 - Voting Results/Scrutinizer Report Of The Postal Ballot Conducted By The Company - Appointment Of Dr. Narendra Mairpady (DIN 00536905) As An Independent Director Of The Company
We are enclosing herewith the results of the voting on the proposed resolution alongwith the Consolidated Report on the voting issued by Ms. Jigyasa N. Ved of M/s. Parikh & Associates, Practising Company Secretaries, scrutinizer appointed for the said Postal Ballot.05-12-2022
Neutral Ipca Laboratories; target of Rs 908: Choice Equity Broking
Choice Equity Broking recommended Neutral rating on Ipca Laboratories with a target price of Rs 908 in its research report dated November 15, 2022.29-11-2022
IPCA LABORATORIES LTD. - 524494 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.24-11-2022
Hold Ipca Laboratories; target of Rs 925: ICICI Direct
ICICI Direct recommended hold rating on Ipca Laboratories with a target price of Rs 925 in its research report dated November 15, 2022.24-11-2022
IPCA LABORATORIES LTD. - 524494 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We are enclosing herewith transcript of our Conference Call which was held on Monday, 14th November, 2022 to discuss the Company's Q2FY23 earnings and business update.16-11-2022
IPCA LABORATORIES LTD. - 524494 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We are enclosing herewith copies of the Unaudited Financial Results for the 2nd quarter and half year ended September 30, 2022 of the financial year 2022-23 published on November 12, 2022 in Free Press Journal, Financial Express and Nav Shakti.14-11-2022
Pharma stock trading at a discount of 23% from the high, 400% dividend declared
With a market valuation of 22,006.03 Cr., IPCA Laboratories Ltd. is a large-cap business that operates in the pharmaceutical industry.11-11-2022
Q2FY23 Quarterly Result Announced for Ipca Laboratories Ltd.
Pharmaceutical firm Ipca Laboratories announced Q2FY23 results: Q2FY23: Standalone net total income up 6% at Rs 1521.47 crore Consolidated net total income up 5% at Rs 1637.18 crore Indian formulations income up 10% at Rs 765.72 crore Exports income down 1% at Rs 628.72 crore Standalone EBITDA margins (before forex (gain)/loss) at 21.04% in Q2FY23, as against at 24.63% in Q2FY22 Consolidated EBITDA margins at 18.84% in Q2FY23, as against at 23.30% in Q2FY22 Standalone net profit at Rs 167.78 crore down 35% Consolidated net profit at Rs 143.90 crore down 42% The board has declared an interim dividend of Rs 4 per share (400%) H1FY23: Standalone net total Income is up 3% at Rs 3,009.56 crore Consolidated net total Income up 3% at Rs 3245.03 crore Indian formulations income is up 11% at Rs 1450.52 crore Exports income is down 6% at Rs 1,316.31 crore Standalone EBITDA margins (before forex (gain) / loss) at 20.29% in H1FY23 as against at 25.89% H1FY22 Consolidated EBITDA margin at 18.92% in H1FY23 as against at 25.34% H1FY22 Standalone Net Profit Rs 311.60 crore down 43% Consolidated net profit at Rs 286.86 crore down 48% Result PDF11-11-2022